A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexMale
Age18+
SponsorBristol-Myers Squibb
About this trial
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Eligibility criteria
Qualifiers
Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
Disqualifiers
Participant must not have history of brain metastases.
Participant must not have impaired cardiac function or clinically significant cardiac disease.
Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.
Trial design
Treatments tested in this trial
- BMS-986460
Treatment groups
140 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov